Is heart rate variability a valuable method to investigate cardiac autonomic dysfunction in subjects with leukemia? A systematic review to evaluate its importance in clinical practice by Kirizawa, Jociele M. et al.
1 
 
IS HEART RATE VARIABILITY A VALUABLE METHOD TO INVESTIGATE CARDIAC 
AUTONOMIC DYSFUNCTION IN SUBJECTS WITH LEUKEMIA? A SYSTEMATIC REVIEW 
TO EVALUATE ITS IMPORTANCE IN CLINICAL PRACTICE 
 
Heart Rate Variability and leukemia 
 
Jociele M. Kirizawa1, David M. Garner2, Claudia Arab3, Vitor E. Valenti1 
 
1Autonomic Nervous System Center, Sao Paulo State University, UNESP, Presidente Prudente, SP, 
Brazil. 2Cardiorespiratory Research Group, Department of Biological and Medical Sciences, Faculty of 
Health and Life Sciences, Oxford Brookes University, Headington Campus, Gipsy Lane, Oxford, OX3 
0BP, United Kingdom. 3Department of Medicine (Cardiology), Federal University of São Paulo 
(UNIFESP), Sao Paulo, SP, Brazil. 
 
* Correspondence to: Vitor E. Valenti 
UNESP, Av. Hygino Muzzi Filho, 737. Mirante 
17.525-900 - Marília, SP. Brazil 





Impaired cardiovascular and autonomic function during treatment and during recovery from leukemia has 
been indicated. In this context, heart rate variability (HRV) is a non-invasive measure that describes the 
oscillations of the intervals between consecutive heart beats (RR intervals); influenced by the autonomic 
nervous system. We intend to review literature showing HRV changes in leukemia subjects.  The articles 
selected in the current review were attained up to March 2018, and the search was limited to articles in 
English language, published in peer-reviewed journals, with both adult and child age samples. The 
articles were investigated in the five electronic databases: PubMed, Physiotherapy Evidence Database – 
PEDro), Cochrane Clinical Trials, Scientific Electronic Library Online - SciELO and Excerpta Medica 
dataBASE – EMBASE. Towards the end of the research, 9 studies were included. Subjects undergoing 
treatment for leukemia have reduced HRV, signifying decreased vagal control of heart rate. The subjects 
that undertook leukemia treatment and their survivors experienced a reduction in HRV with subsequent 
recovery, but the recovery time is ill defined. HRV is reduced in leukemia subjects who progress to 
neuropathy secondary to chemotherapy, accompanied by cardiac dysfunction. We advocate the use of 




Keywords: Autonomic Nervous System; Cardiovascular Physiology; Heart Rate; Leukemia, Myeloid 







This review indicates appropriate studies that assessed HRV in subjects with leukemia. The 
references demonstrated reduced HRV in leukemia subjects who progressed to neuropathy secondary to 
chemotherapy, accompanied by cardiac dysfunction. Thus, HRV can be applied to evaluate autonomic 
dysfunction and possibly help to modify the treatment with the purpose of preventing further autonomic 








Lymphoid leukemia is the principal neoplasm affecting children and adolescents worldwide. Its 
incidence is 25% to 30%, and has two age peaks. The first is between three and seven years old and the 
second is over forty years old. Risk factors are related to age and responses to chemotherapy, yet, the 
identification of recurrent genetic alterations has facilitated the refinement of the individual prognosis and 
clinical management [1–3]. 
Leukemia is a malignant and progressive hematological disease that originates in the bone marrow 
where the blood cells are produced. It is noticeable by the proliferation and mutations of these cells, and 
may or may not occupy other locations, invading the circulatory system, since it is a blood neoplasm. It is 
classified as an acute (95%) or chronic (5%) leukemia [2]. 
Acute myeloid leukemia and acute lymphoblastic leukemia are amongst the acute leukemias and 
are highly aggressive, necessitating early treatment. Chronic leukemias, including chronic myelogenous 
leukemia and chronic lymphocytic leukemia are categorized by proliferation of mature cells. In this 
grouping of leukemia, the mutation permits the maintenance of differentiation capacity and cell 
maturation, with an increase in the number of mature cells in the bone marrow and the peripheral blood. 
The disease progression is slow; yet, it is followed by an accelerated phase and may later develop into 
acute leukemia. The most prevalent type, in children, is lymphoblastic leukemia. The main clinical 
manifestations are fever, bleeding, anemia, fatigue and recurrent infections [2, 4]. Furthermore, the 
literature reports impaired cardiovascular and autonomic function in leukemia during treatment and 
improvement after the necessary pharmacological treatment [5–7]. 
In this way, heart rate variability (HRV) is a simple and non-invasive method that describes the 
oscillations of the intervals between consecutive heart beats (RR intervals), and is influenced by the 
autonomic nervous system. Its applicability is vast and is able to identify phenomena related to autonomic 
function in healthy individuals, athletes and subjects with diseases [8, 9]. 
There appears to be an immunological interaction between the malignancy and the peripheral 
nervous system dysfunction, suggesting that the HRV of subjects with leukemia is more exaggerated in 
those with a more compromised clinical feature [6]. So, autonomic function is affected in cancer subjects. 
This could result from the cancer or cancer treatments [10]. 
A cohort study evaluated 651 subjects with hematologic malignancies submitted to autonomic 
cardiac evaluation at the cancer outpatient clinic between 2008 and 2011. This study proposed an 
association between HRV (specifically in the time domain) and subjects’ survival time [11]. 
HRV analysis delivers valued information for subjects under physiological and pathological 
conditions [10]. Given that the interaction between cancer, chemotherapy and HRV that has been 
previously defined, we raised the following questions: what is the evidence for the effects of leukemia on 
HRV? Is there a connection between the leukemia treatments and HRV deviations? Is HRV a good way 
to evaluate subjects with leukemia? To answer these questions, we performed a systematic review that 







We performed a systematic review according to the ‘Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses’ (PRISMA) Statement [12].  
Information sources 
The articles in the current review were obtained in journals up to March 2018. These searches 
were limited to articles in English language, published in peer-reviewed journals, and with adult and child  
samples only. The articles were investigated in five electronic databases: PubMed 
(https://www.ncbi.nlm.nih.gov/pubmed), Physiotherapy Evidence Database – PEDro 
(https://www.pedro.org.au/), Cochrane Clinical Trials (https://www.cochranelibrary.com), Scientific 
Electronic Library Online - SciELO (http://www.scielo.org) and Excerpta Medica dataBASE - EMBASE 
(https://www.embase.com). 
Search strategy, inclusion and exclusion criteria 
The following terms were applied for the combination of groups of descriptors: "autonomic 
nervous system", "heart rate variability", "sympathetic nervous system", "vagal nerve", "parasympathetic 
nervous system", "leukemia" and "humans". The Boolean operator “AND” was necessary in the grouping 
of the synonyms of the descriptors of the same cohort.  
These searches were undertaken without a limit on the year of publication. No filters were 
necessary to select the studies. 
Initially, we commenced with a selection of titles related to the topic. This selection was based on 
evidence that related HRV with leukemia; duplications were excluded. Moreover, manuscripts that 
examined leukemia and varied types of cancers. Next, abstracts were assessed, according to those that 
studied HRV in subjects with leukemia only. We excluded abstracts unrelated to that issue. The full texts 
were examined, then those that were not suitable regarding the exclusion criteria were excluded in the 
current review. Likewise, a search was made in the references of the full texts. 
So as to increase reliability in the selection of articles, all search and selection stages were 
reviewed independently by two investigators, and after reading the articles, reached a consensus to 
establish which articles should be included [12]. 
Data extraction process 
Data extraction and management of the involved articles were achieved in duplicate (two 
reviewers independently). We nominated articles based on the PICOS (Subject, Intervention, Control, 
Outcomes, Study Type) criteria: 
Study eligibility criteria 
Subject 
We included studies with humans who were being treated or have undergone leukemia and other 
types of cancer treatment. 
Intervention / Control 
We included references that involved studies evaluating HRV in leukemia subjects and survivors, 
with or without a control group. We also involved studies that evaluated the effects of pharmacological 




The principal outcome measured were the linear and nonlinear indices of HRV: RMSSD (square 
root of the mean square of the differences between adjacent normal RR intervals), SDNN (standard 
deviation of all normal RR intervals), pNN50 (percentage of adjacent RR intervals with duration 
difference greater than 50 milliseconds), HF (high frequency), LF (low frequency), LF/HF ratio (Relation 
between low and high frequency components), SD1 (dispersion of points perpendicular to the identity 
line, instantaneous record of beat-to-beat variability), SD2 (scatter points along the identity line, long-
term record). 
Study Type 
The references selected included any type of study design, yet, we did not include letters to editor, 
commentaries and reviews. 
Data analysis 
The leading and essential criterion was that all details concerning HRV analysis should be 
described in selected studies, explicitly: description of protocol, data collection, instruments and HRV 
analysis methods. Next, datasets were evaluated based on the subjects, ethical considerations (informed 
written consent and committee ethic approval), and detailed data collection procedures in selected studies. 
At least two of the following items were required to be considered for the current review: (a) inclusion 
and exclusion criteria, (b) comparison between groups, (c) sample loss, and (d) sample size. 
We followed guiding principles from the Grades of Recommendation, Assessment, Development, 
and Evaluation (GRADE) Working Group [13]. The main feature to be considered in the strength of 
evidence was study design, categorized as observational studies (low evidence) and randomized trials 
(high evidence). Study quality (detailed study methods and execution) and presence of limitations were 
considered in strength of evidence analysis. 
RESULTS 
Selection of studies 
In the preliminary literature search, we identified 161 publications in databases. After eliminating 
the duplicates, 159 studies had their titles and abstracts read. After the first stage, 13 articles needed to be 
read in entirety. At the end of the research, nine studies were included. The reviewers approved the 
identification of the remaining nine studies using the abovementioned eligibility criteria. Figure 1. 
Characteristics of studies. 
The specific characteristics of each study were detailed in Table 1 with the following information: 
Authors’ name, year; Population; HRV analysis and Main Results. The revised studies addressed the 
following topics: Four manuscripts that evaluated the effects of chemotherapy on autonomic modulation 
assessed through HRV, with at least two data collections; three manuscripts that investigated HRV in 
leukemia survivors (post-treatment); and two manuscripts that examined the effects of different 
treatments on HRV in leukemia subjects. 
Chemotherapy & HRV 
In this evaluation, four articles addressed the effect of chemotherapy on autonomic modulation 
assessed through HRV: two evaluated the effect of treatment with ‘VinCristine’, - a chemotherapy 
medication [5, 14] . One study evaluated the effect of arsenic trioxide in a group that was unsuccessful 
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with traditional chemotherapy treatment [15]. Another single investigation evaluated the effect of 
hematopoietic stem cell transplantation after treatment with high doses of chemotherapy [16]. 
In all studies, HRV was revealed to be reduced in leukemia [5, 14–16]. Also, three studies 
described that HRV tended to increase gradually with discontinuation of treatment, yet, recovery time is 
ill defined and could take months to years [5, 14, 15]. 
In one study the subjects presented cardiac arrhythmia and QT prolongation, perhaps as a 
consequence of damage in cardiac autonomic regulation [15]. 
Post-Treatment & HRV 
In this appraisal, three articles evaluated HRV in leukemia treatment survivors. Only one of the 
reviewed study’s had a healthy control group [7]. The results strengthened the concept that the treatment 
largely affects the parasympathetic system. Nevertheless, LF activation in the orthostatic position is 
infrequently noticed and the small decrease in HR advocates that there is an alteration in the sympathetic 
system too. The authors grouped the population by gender and compared the control to the leukemia 
group. The results indicated that the HR autonomic control of young and healthy women is together more 
complex and susceptible to damage caused by neurotoxic substances, such as chemotherapy. 
Furthermore, this study reinforced the hypothesis that cardiac neural regulation assessed by HRV is 
transformed in subjects who have their leukemia treated, but not reversed after the end of their treatment 
[9]. 
A study conducted by Zeller et al, [17] evaluated adult survivors of childhood leukemia treatment 
and split them into two groups: the first group included subjects suffering from chronic fatigue, and the 
control group included subjects who did not suffer chronic fatigue. Head-up tilt test was completed for 
cardiovascular and autonomic analysis. The subjects’ remained in both positions for five minutes, lying 
flat and at an inclined slope of 20º for Electrocardiogram (ECG) analysis. There was no alteration in the 
results between the groups. This may be justified by the time or slopes applied that were possibly 
insufficient to generate sufficient cardiovascular and autonomic changes. 
One more study has established through HRV, that is decreased in subjects with leukemia, and this 
highlighted that there is a sympathetic predominance in relation to the parasympathetic system [6]. 
Alternative Therapies & HRV 
In this study, two articles addressed HRV and alternative treatments  [18, 19]. Kemper et al, in 
order to evaluate complementary relaxation treatments, directed two studies [18, 19]. The first study 
applied energy healing-based therapies as a tool to assess the relaxation state of children with leukemia 
[18]. Two evaluations were achieved and the subjects were their own controls.  Also, the technique was 
performed by a person unfamiliar to the children. There was inferior sympathetic activation when the 
subjects were exposed to energy healing-based therapy. In contrast, there was no significant effect on the 
equivalent scale of stress. Since it was a study with a large range of ages, and in some cases, the parents 
of subjects assisted completion of the stress scale. Additionally, the study did not report how parents 
completed the scale and the hypothesis raised was that they projected their own feelings or did not have 
the sensitivity to subtle changes in the children’s temperaments. Previously, it was suggested that the 
sensation of well-being is related to the increase of the activity of the parasympathetic nervous system 
and decrease of the activity of the sympathetic nervous system [18]. 
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  In a further study, Kemper et al, [19] performed two assessments to analyze the impact of music 
on the relaxation feeling in the same population. In that study, the stress scale presented relaxant and 
well-being effects of music, whilst during HRV a reduction in the parasympathetic control of the HR was 
reported. 
Yet again, parents completed the stress scale with the help of their children and reported high 
relaxation and low stress on the first questionnaire. It is worth highlighting that relaxation was the sole 
item with expressive results. 
An unexpected finding was the reduction in the parasympathetic regulation of the cardiac rhythm, 
represented by the HF band [19]. 
DISCUSSION 
In order to provide a suitable analysis regarding the use of HRV in leukemia, we performed a 
systematic review. In general, the analysis of selected studies indicated that: 1) subjects undergoing 
treatment for leukemia have reduced HRV, suggesting decreased vagal control of HR; 2) subjects who 
underwent leukemia treatment and survived have a reduction in HRV with subsequent recovery, but the 
recovery time is still ill defined. 
Although the first article of this review is from 1989, ‘VinCristine’ is a medication that is still 
currently a part of the standard leukemia treatment protocol and, the authors were able to form a small 
and homogeneous sample with children newly diagnosed with leukemia. All children in the study began 
treatment with six doses of ‘VinCristine’. This pharmacological treatment was shown to weaken the 
interaction between breathing and autonomic HR control, which suggests a parasympathetic damage in 
leukemia children. In the aforementioned study, HRV in children with leukemia significantly decreased 
during ‘VinCristine’ treatment. Yet, this reduction appears to be alterable with the cessation of the 
medication [14]. 
Recently, another study evaluated the effect of ‘VinCristine’ on neuropathy focusing on autonomic 
dysfunction in children with leukemia [5]. Although peripheral neuropathy was more prevalent than 
autonomic neuropathy when associated with ‘VinCristine’ use, the two conditions seemed to occur 
concomitantly in that study. The deviations appear caused by this drugs regression at the end of its use, 
yet, the recovery time is not well defined, and could take months to years. This study selected only 
subjects who presented severe neuropathy previously detected through the medical diagnostic plan and 
did not account at which stage of treatment the subjects were at [5]. Together, these datasets suggest that 
the clinical team should be careful concerning the use of ‘VinCristine’, since it is shown to impair 
autonomic function. 
In contrast, Kamath et al, demonstrated that the impairment of the autonomic HR control induced 
by antineoplastic agents is not reversible in survivors who received leukemia treatment including 
radiotherapy [7]. 
An article published by Nevruz et al, reinforced that HRV is decreased in subjects with leukemia. 
This study was founded on biochemical analysis; the leukemia subjects had low hemoglobin and 
hematocrit, reflecting an anemic state. So, they suggested undertaking research with a group composed of 
anemic subjects to exclude the possibility of influence of anemia on HRV reduction caused by leukemia. 
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This article confirmed an autonomic imbalance in subjects with leukemia and provided substantial 
evidence concerning prediction of subclinical neuropathy in subjects with leukemia [6]. 
Considering the numerous changes that leukemia induces physiologically, chronic fatigue is one of 
the complaints. Zeller et al, reported a higher score in the fatigue questionnaire in leukemia subjects 
compared to control subjects. Although the leukemia group had lower blood acetylcholine levels, which 
led us to expect diminished HRV; there was no significant difference of HRV between groups. In the 
head-up tilt test, the groups presented the expected changes, hence: increased blood pressure and HR. 
Conceivably, if the authors applied other tests or protocols with the treadmill stress test the results could 
be different [17]. 
Since leukemia is a serious disease and requires rapid treatment initiation, some studies [15, 16] 
have inevitably revealed some bias. In the Poreba study (2014), the subjects were submitted to high doses 
of chemotherapy followed by transplantation of hematopoietic stem cells. That study demonstrated 
significantly decreased HRV following receiving hematopoietic stem cell transplantation when compared 
prior to receiving chemotherapy [16]. 
The same study described changes in HRV and heart rate turbulence, which were indicated to be 
related to the transplantation procedure [16]. Yet, it is acknowledged that chemotherapy can cause a 
decrease in HRV [20]. So as to elucidate this query, an additional evaluation would be necessary at the 
end of the chemotherapy, nonetheless the subjects were debilitated and at risk of death and thus this 
additional evaluation is not possible. 
A similar situation was investigated by Takeshita et al, the study evaluated HRV in subjects who 
had failed chemotherapy treatment and initiated daily therapy with arsenic trioxide. Overall, all subjects 
presented reduced HRV, cardiac arrhythmias and QT prolongation, undoubtedly due to damage in cardiac 
autonomic regulation. The parameters examined in the first evaluation were performed three weeks after 
treatment onset due to urgency and risk of death [15]. 
The results presented by Kemper et al, although significant in the analysis of HRV, when 
compared to the analogue stress scale seem contradictory. It is worth stating that this study highlighted 
the difficulty of working with children. The authors elected for a reduced stress scale (considering the 
additional time that parents and children would remain in the outpatients’ clinic), which may have 
prejudiced the results. Some children, owing to age, needed parental help to fill the scale by raising the 
hypothesis of parents projecting their own feelings and/or not perceiving subtle changes in children's 
temperaments [18, 19]. 
Alternative treatments were also revealed in this systematic review. Music was one of the therapies 
included [19]. In this study, the authors described music as a variable able to relax the body, reducing 
anxiety, fatigue and stress and increasing vitality. The decrease in the parasympathetic regulation of the 
heart rhythm, represented by a weakened HF band; can be justified by the fact that it is not pleasant for 
children to remain 30 to 40 minutes at rest, listening to unfamiliar music. Considering well-being and 
relaxation, in order to familiarize the children with the procedures, if more than one visit was required 
and, if they played music the children liked, they could become more relaxed [19]. 
Another alternative therapy used was energy healing-based therapy [18]. The authors evaluated the 
impact of this intervention on HRV and stress in subjects with leukemia. As a key result, it was unable to 
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find significant influence of energy healing-based therapy on the aforesaid variables. So, we should be 
vigilant with alternative therapies for cancer treatment [18]. 
Our review offers some significant points to be highlighted. 1) Most of the studies were composed 
only by volunteers with diagnoses of leukemia, which implied a small statistical sample. 2) Regarding the 
references cited, we found an array of studies with larger samples, diagnosis of different types of cancers 
and age ranges. 3) There were no randomized clinical trials and meta-analysis. So, this systematic review 
did not contain high evidence studies. 
 
CONCLUSIONS 
In summary, we reported suitable studies that assessed HRV in subjects with leukemia. The 
references demonstrated HRV reduction in leukemia subjects who progressed to neuropathy secondary to 
chemotherapy, accompanied by cardiac dysfunction. So, HRV can be enforced to evaluate autonomic 
impairment and, if at all possible, change the clinical treatment to prevent further impairment of 
autonomic function. The relevance of employing HRV as an indicator of risk factor for evaluating and 
identifying health impairments related to autonomic function is encouraging. We emphasize HRV as a 
clinically reliable and complementary approach to evaluate early diagnosis of autonomic dysfunction in 
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Table I: Summary of selected studies investigating the clinical importance of HRV analysis in leukemia 
patients. 
Selected articles Study participants HRV analysis  Main Results 
Hirvonen et al. 1989 Acute lymphoblastic 
leukemia treated with 
chemotherapy. 
(five men, four 
women) 
Age range: 2.5 – 14 
years. 
 
HRV was evaluated through 
ECG. Two tests were carried 
out, one was performed in the 
first dose of Vincristine. 
The second was held between 
the fifth and sixth dose of 
Vincristine. 
It was performed a follow-up 
from 3rd to 22nd week. 
Protocol: 5 minutes 
spontaneous breathing, 
followed by 2 minutes of deep 
and controlled breathing.  
HRV was reduced during treatment with 
subsequent recovery after treatment. 
 
Kamath et al. 1998 
 
 
Leukemia Group: n n = 
34 (13 women). 
Age range: 5 -21 years 
old. 
Five subjects treated 
with cranial radiation, 
seven with fractional 
cranial radiation and 21 
HRV was analyzed trough 24 
hours Holter.  
As a familiarization, the 
subjects went to the laboratory 
and ECG was recorded 30 
minutes in bench press and 10 
minutes in Orthostatism. 
Bench press: LH/HF and LF were higher 
and HF decreased in the Leukemia Group 
compared to the control group (p < 0.001).  
Orthostatism: HR, LH/HF, and LF were 
higher and HF lower in the control group. 
No difference in HRV time domain was 
noted. 





Control Group: 34 
subjects (15 women). 
 
in the control group. 
Genre: Bench Press, LF/HF was decreased 
in women than men (both groups). 
Control: LF difference throughout the day 
among women. 
Leukemia: Attenuated HF in women. 
Cranial radiation effect: Significant 
differences between patients who received 
traditional radiation and those who received 
hyper-fractional radiation. 
Higher values of LF/HF and LF were 
observed in the conventional radiation group 
compared to control group. 
Takeshita et al. 2004 
 
 
Six subjects with acute 
promyelocytic 
leukemia who relapsed 




Daily treatment with arsenic 
trioxide (minimum of 25 days 
and a maximum of 60 days). 
HRV was evaluated through 
24-hour Holter after three 
weeks of treatment and one 
week prior to termination of 
treatment. 
 
QT wave prolongation appeared in all 
subjects (p <0.04) 
HRV significantly decreased during 
treatment: LF (p=0.028), SDNNA 




Nevruz et al. 2007 
 
 
Intervention group: 36 
subjects with acute 
leukemia recently 
diagnosed. (14 acute 
lymphoblastic 
leukemia, 22 acute 
myeloblastic leukemia) 
(11 women). 
HRV was analyzed via 24 
hours Holter. 
HRV was decreased in patients with 




Mean Age 34 + 16 
years old. 
Control group: 32 
healthy subjects. 
(9 women). 
Mean Age: 30 + 10 
years old. 








47 subjects (9 women), 
36 leukemia subjects 
and 11 subjects with 
another type of cancer. 
Mean age: 10.4 + 5.1 
years old. 
Age Range: 8 to 17.9 
years old. 
Cohort study 
conducted between May 2004 
and May 2007. 
Subjects responded to a stress 
scale with help from their 
parents. 
Score ranged from 0 – 10. 
HRV was analyzed. 
In the subjective stress scale, the participants 
gave a high score for the positive points and 
a low score on the negative points on the 
first visit. Only the relaxation item showed a 
significant result after the intervention with 
the music (HF, p<0.01). 
Kemper et al. 2009 
 
 
Five subjects with 
leukemia and one with 
another type of cancer 
(three men). 
Mean age: 8.7 + 4.3 
years old. 






There were 2 visits. 
Visit 1: usual care and rest in 
quiet room for 20 minutes. 
Visit 2: usual care and rest in 
quiet room, receiving energy 
healing-based therapy. 
At both visits, the children 
answered a stress 
questionnaire before and after 
the procedure. 
HRV was analyzed. 
There was a significant decrease in the 
negative state of the stress scale after the 
energy healing based therapy. Total power 
was decreased during healing touch therapy 
(p < 0.05). 
Zeller et al. 2014 
 
Intervention group: n = 
32 (25 women) 
Subjects performed the Head-
up tilt test: they were placed 
The intervention group showed significantly 
higher score in the fatigue questionnaire. 
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 survivors of leukemia 
treatment. 
Mean age: 32.7 years 
old. 
Age range: 22.7 to 50.7 
years old.  
Control: 
n = 52 (26 women) 
subjects.  
Mean age: 34 years 
old. 
Age range: 20.5 to 53.1 
years old. 
horizontally on the orthostatic 
table and remained for five 
minutes recording the RR 
intervals and additional five 
minutes with a slope of 20 
degrees. 
Blood pressure and HRV were 
analyzed.  
Subjects also answered fatigue 
questionnaire. 
Blood and urine analysis 
(Epinephrine, cortisol, 
norepinephrine) were made. 
Autonomic Symptoms also improved: 
↓Palpitations (p<0.001), ↓feeling 
intermittently heat and cold (p<0.004), 
↓lightheadedness (p<0.02), ↓watery diarrhea 
(p< 0.001) in the control group. 
↑ Acetylcholine (p<0.002) in the control 
group. 
↓Urine norepinephrine (p<0.017) in control 
group. 
There was no significant difference between 




38 subjects with 
leukemia, 18 with 
leukemia lymphoid and 
myeloid, seven with 
Hodgkin’s lymphoma, 





submitted to high doses 
of chemotherapy, in a 
course of 
hematopoietic stem cell 
transplantation 
 n =15 F, n = 23 M 
Mean age: 42.88 + 
First examination: Before 
chemotherapy treatment, 
followed by cell 
transplantation. 
22 patients received 
autologous cells and 16 
patients received allogenic 
cells 
Blood tests. 
ECG and Holter-24 hours 
were performed for HRV 
analysis. 
Second examination: About 
20 days after completing the 
cell transplantation, followed 
by chemotherapy. Holter-24 
hours was repeated for HRV 
Individuals with hematopoietic malignancies 
treated with  hematopoietic stem cell 
transplantation evidenced decreased HRV 
and HR turbulence after  stem cells 
administration and chemotherapy. 
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Legend: HRV: heart rate variability; ECG: electrocardiogram; SDNN: standard deviation of all normal-
to-normal intervals; LF: low frequency; HF: high frequency; RMSSD: square root of the mean of the sum 
of the squares of differences between successive normal-to-normal intervals; HRV index: number of all 
normal-to-normal intervals divided by the maximum of all normal-to-normal intervals; LF/HF ratio: low 
to high frequency ratio VLF: very low frequency; SDANN: standard deviation of the averages of normal-
to-normal intervals in all 5 min periods of the recording; PNN50: number of pairs of successive normal-
to-normal intervals differing by more than 50 ms, divided by the total number of normal-to-normal 
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19 subjects selected 
through the electronic 
medical record from 
2006 to 2016 (10 men). 





Age Range: 2 to 14 
years old. 
Head-up tilt test: they were 
placed on the orthostatic table 
for five minutes and then 
positioned on a 70-degree 
inclination, remaining in that 
position for 10 minutes. 
The following cardiovascular 
parameters were assessed: 
Heart rate, blood pressure, 
stroke volume, peripheral 
resistance. 
HRV was analyzed in the time 
domain. 
 
The authors concluded that HRV was able to 
provide significant clinical information 
regarding autonomic dysfunction. 
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